News Releases Keyword Search Year None20242023202220212020201920182017201620152014 Dec 11, 2024 Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock Dec 10, 2024 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Nov 26, 2024 Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference Nov 18, 2024 Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference Nov 12, 2024 Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions Nov 08, 2024 Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference Nov 07, 2024 Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress Sep 17, 2024 Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease Sep 10, 2024 Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors Aug 27, 2024 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Aug 05, 2024 Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress Jun 28, 2024 Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) May 29, 2024 Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy May 10, 2024 Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 06, 2024 Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress Apr 02, 2024 Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia Mar 26, 2024 Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team Feb 26, 2024 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress Feb 13, 2024 Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Jan 02, 2024 Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference Print Page RSS E-mail Alerts Contact
Keyword Search Year None20242023202220212020201920182017201620152014 Dec 11, 2024 Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock Dec 10, 2024 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Nov 26, 2024 Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference Nov 18, 2024 Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference Nov 12, 2024 Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions Nov 08, 2024 Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference Nov 07, 2024 Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress Sep 17, 2024 Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease Sep 10, 2024 Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors Aug 27, 2024 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Aug 05, 2024 Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress Jun 28, 2024 Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) May 29, 2024 Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy May 10, 2024 Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 06, 2024 Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress Apr 02, 2024 Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia Mar 26, 2024 Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team Feb 26, 2024 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress Feb 13, 2024 Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Jan 02, 2024 Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
Nov 18, 2024 Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
Nov 12, 2024 Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
Nov 07, 2024 Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Sep 17, 2024 Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
Sep 10, 2024 Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
Aug 05, 2024 Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
Jun 28, 2024 Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
May 29, 2024 Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
May 10, 2024 Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 06, 2024 Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Apr 02, 2024 Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Mar 26, 2024 Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Feb 26, 2024 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Feb 13, 2024 Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
